Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Replimune, Inc.
Modality
gene_therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04349436CT.gov Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Skin Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oncolytic Virus Rp1 (this asset) | Replimune, Inc. | P1/2 | CCC · 48 |
| Prednisone | Dana-Farber Cancer Institute | P4 | BB |
| Sirolimus | Dana-Farber Cancer Institute | P4 | BB |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P3 | BB |
| Everolimus | Dana-Farber Cancer Institute | P4 | BB |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | BB |
| Indocyanine Green | Institut de Cancérologie de Lorraine | P3 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P2 | B |
| Nivolumab | Fred Hutchinson Cancer Center | P2 | B |
+42 more in the Skin Squamous Cell Carcinoma cohort
Other indications for Oncolytic Virus Rp1
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P3 | B · 58 |
| Skin Carcinoma | — | P2 | CCC · 53 |
| Cutaneous Melanoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PrednisoneDana-Farber Cancer InstituteBB
- SirolimusDana-Farber Cancer InstituteBB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsBB
- EverolimusDana-Farber Cancer InstituteBB
- Technetium-99Institut de Cancérologie de LorraineBB
Citation
Floatz Terminal. Oncolytic Virus Rp1 in Skin Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oncolytic-virus-rp1-skin-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →